- Combination of Paclitaxel and Nitric Oxide as a Novel Treatment for the Reduction of Restenosis
-
The combination of a nitric oxide (NO) donor and a paclitaxel-NO donor conjugate coated on a vascular stent was tested in a rabbit iliac artery model of stenosis as a potential therapy for restenosis. Paclitaxel was conjugated with a NO donor at the 7-pos
- Lin, Chia-En,Garvey, David S.,Janero, David R.,Letts, L. Gordon,Marek, Przemyslaw,Richardson, Stewart K.,Serebryanik, Diana,Shumway, Matthew J.,Tam, S. William,Trocha, A. Mark,Young, Delano V.
-
-
Read Online
- Phosphodiesterase inhibitor compounds and nitric oxide donors
-
The invention provides phosphodiesterase inhibitors and/or nitric oxide donors that are useful in treating male impotence, female sexual dysfunction and anal diseases.
- -
-
Page/Page column 21
(2008/06/13)
-
- Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
-
The invention provides methods for treating female sexual dysfunctions by administering to a female individual a therapeutically effective amount of at least one compound that donates, transfers or release nitrogen monoxide, that induces the production of
- -
-
-
- L-Cysteine as a water-soluble cation scavenger in the removal of the 2,4,6-trimethoxybenzyl group from thiols
-
L-Cysteine was used as a water-soluble cation scavenger in the acid-catalyzed removal of the 2,4,6-trimethoxybenzyl (Tmob) group from thiols. After aqueous extraction, the product thiols were isolated in good yields. For most substrates, trifluoroacetic acid (TFA) is the reagent of choice. However, for the deprotection of acid-sensitive compounds, formic acid with an extended reaction time is appropriate.
- Lin, Chia-En,Richardson, Stewart K,Garvey, David S
-
p. 4531 - 4533
(2007/10/03)
-
- Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
-
The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donat
- -
-
-
- Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
-
The present invention describes novel compositions and kits comprising alpha-adrenergic receptor antagonists and compounds that donate, transfer or release nitric oxide, elevate endogenous levels of endothelium-derived relaxing factor, or stimulate nitric
- -
-
-
- Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
-
Disclosed are nitrosated and nitrosylated α-adrenergic receptor antagonists, compositions of an α-adrenergic receptor antagonist (α-antagonist), which can optionally be substituted with at least one NO or NO2 moiety, and a compound that donates
- -
-
-
- Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders
-
Disclosed are (i) compounds of a steroid, a β-agonist, an anticholinergic, a mast cell stabilizer and a phosphodiesterase (PDE) inhibitor directly or indirectly linked to a NO or NO2 group or a group which stimulates endogenous production of NO or EDRF in vivo; (ii) compositions of steroids, β-agonists, anticholinergics, mast cell stabilizers and PDE inhibitors, which can optionally be substituted with at least one NO or NO2 moiety or a group which stimulates endogenous production of NO or EDRF in vivo, and a compound that donates, transfers or releases nitric oxide as a charged species, i.e., nitrosonium (NO+) or nitroxyl (NO-), or as the neutral species, nitric oxide (NO.circle-solid.) or that stimulates endogenous production of NO or EDRF in vivo; and (iii) uses for them in preventing and/or treating respiratory disorders.
- -
-
-